ZBIO
Zenas BioPharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.79
+0.07%Oct 6, 2026, 11:05 UTC
Zenas BioPharma announced it will host a virtual R&D event on October 27, 2026.
Source:Sep 22, 2026, 11:05 UTC
Zenas BioPharma announced upcoming presentations of obexelimab data in IgG4-related disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026.
Source:Aug 13, 2026, 11:00 UTC
Zenas BioPharma's CFO will transition to Strategic Advisor to the Board Chair at the end of September.
Source:Aug 13, 2026, 11:00 UTC
Zenas BioPharma expanded its Board of Directors with the appointment of Christy Oliger, who brings more than 30 years of global biopharmaceutical commercial and operating experience.
Source:Aug 13, 2026, 11:00 UTC
Zenas BioPharma reported financial results for the quarter ended June 30, 2026, with cash, cash equivalents and investments of $673.9 million as of that date.
Source:Aug 13, 2026, 11:00 UTC
The FDA accepted Zenas BioPharma's BLA submission for obexelimab for the treatment of IgG4-RD, with a PDUFA target action date of May 27, 2027.
Source:Jun 21, 2026, 11:34 UTC
Leon O. Molder Jr., CEO of Zenas BioPharma, purchased 60,000 company shares in an open-market transaction.
Source:Jun 2, 2026, 23:05 UTC
Zenas BioPharma announced positive Phase 3 INDIGO trial data for obexelimab in IgG4-RD at the EULAR 2026 Congress and in the New England Journal of Medicine.
Source: